AUTL Valuation

Autolus Therapeutics PLC

Add to Watchlist

Advanced Chart

2.555

-0.085(-3.220%)1D

Overview
Forecast
Valuation
Earnings

AUTL Relative Valuation

AUTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AUTL is overvalued; if below, it's undervalued.

Historical Valuation

Autolus Therapeutics PLC (AUTL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.32 is considered Undervalued compared with the five-year average of -3.26. The fair price of Autolus Therapeutics PLC (AUTL) is between 4.79 to 9.49 according to relative valuation methord. Compared to the current price of 2.55 USD , Autolus Therapeutics PLC is Undervalued By 46.8%.

Relative Value

Fair Zone

4.79-9.49

Current Price：2.55

46.8%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.92

P/B

Median3y

2.42

Median5y

2.14

-38.01

FCF Yield

Median3y

-31.41

Median5y

-32.15

Competitors Valuation Multiple

The average P/S ratio for AUTL's competitors is 72.87, providing a benchmark for relative valuation. Autolus Therapeutics PLC Corp (AUTL) exhibits a P/S ratio of 10.32, which is -85.84% above the industry average. Given its robust revenue growth of -10.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AUTL.O

Autolus Therapeutics PLC

10.32

Average P/S: 72.87

-10.99%